GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

camrelizumab   Click here for help

GtoPdb Ligand ID: 9758

Synonyms: INCSHR1210 | SHR-1210
Approved drug Immunopharmacology Ligand
camrelizumab is an approved drug (China (2019))
Compound class: Antibody
Comment: Camrelizumab is a fully human anti-programmed cell death 1 (PD-1) monoclonal antibody being developed as an immuno-oncology therapeutic.

SARS-CoV-2 and COVID-19: Clinical efficacy of camrelizumab plus thymosin in patients with COVID-19 will be evaluated in clinical trial NCT04268537.
Classification Click here for help
Compound class Antibody
Approved drug? Yes. China NMPA (2019)
International Nonproprietary Names Click here for help
INN number INN
10400 camrelizumab
Synonyms Click here for help
INCSHR1210 | SHR-1210
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 659
Reactome Drug Reactome logo R-ALL-9679471
Reactome Reaction Reactome logo R-HSA-9679421
Other databases
GtoPdb PubChem SID 354702231
Search PubMed clinical trials camrelizumab
Search PubMed titles camrelizumab
Search PubMed titles/abstracts camrelizumab